TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). Meeting Abstract

cited authors

  • Agarwal, Neeraj; Shore, Neal D.; Dunshee, Curtis; Karsh, Lawrence Ivan; Sullivan, Beth; Di Santo, Nicola; Elmeliegy, Mohamed; Lin, Xun; Quek, Ruben G. W.; Czibere, Akos Gabor; Fizazi, Karim

Publication Date

  • May 20, 2019

webpage

published in

category

volume

  • 37

issue

  • 15